PURPOSE. Inflammation generates changes in the protein constituents of the aqueous humor. Proteins that change in multiple models of uveitis may be good biomarkers of disease or targets for therapeutic intervention. The present study was conducted to identify differentially-expressed proteins in the inflamed aqueous humor.
T he term ''uveitis'' describes a heterogeneous set of conditions that all feature intraocular inflammation. 1 Ocular inflammation leads to an increase in the protein concentration in the aqueous and vitreous humors of the eye. 2 The increased protein results from the influx of serum proteins during inflammation-mediated breakdown of the blood-ocular barrier, and increased local production of inflammatory mediators by resident and recruited immune cells. Normal human aqueous contains between 50 and 676 proteins, many with antioxidant, immunoregulatory, and antiangiogenic functions. 3, 4 Previous studies [5] [6] [7] have evaluated changes in the protein concentration and composition of the aqueous humor in diseases such as glaucoma, macular degeneration, and vein occlusion with macular edema. These studies have identified changes in total protein concentration and protein composition that have correlated with disease progression and prognosis. However, none of these diseases experience the dramatic changes in intraocular protein seen as a result of the inflammation caused by uveitis. [8] [9] [10] [11] In the equine recurrent uveitis (ERU) model of uveitis, changes in the lymphocyte proteome that occur during active inflammation have been described. 12 Additionally, in the rat models of endotoxin-induced uveitis (EIU) and experimental autoimmune uveitis (EAU), vitreous proteome studies have been performed on the vitreous that identified posttranslational modifications and truncations of a-crystallins in association with inflammation. 13, 14 However, these studies all compare one model of uveitis to the naïve condition. In this study, we compared the naïve aqueous humor proteome to two rat models of uveitis: EAU and primed mycobacterial uveitis (PMU). Experimental autoimmune uveitis is a well-established model of noninfectious T-cell-mediated autoimmune uveitis. 15 Primed mycobacterial uveitis is a model of uveitis recently adapted from rabbits to the rat by our group (accompanying manuscript). Owing to the introduction of killed mycobacteria into the vitreous cavity, innate immunity plays a significant role in this form of uveitis. By using two mechanistically different forms of uveitis, comparative proteome analysis will help to identify protein changes common to both forms of uveitis, as well as proteins that may be specific to each form of inflammation.
METHODS Experimental Animals and Uveitis Induction
Induction of PMU in 15 Lewis rats was initiated with a subcutaneous injection in the right hind flank of 100 lg mycobacterium tuberculosis H37Ra antigen (Difco Laboratories, Detroit, MI, USA) in 0.1 mL suspension of 50% peanut oil and 50% phosphate-buffered saline (PBS). Seven days later the right eye received a 5 lL intravitreal injection of 1 mg/mL suspension of mycobacterium tuberculosis H37Ra antigen in PBS. A second group of 15 female Lewis rats received the same subcutaneous injection of mycobacterium tuberculosis H37Ra antigen, but 7 days later received an intravitreal injection of 5 lL PBS in the right eye (sham injection group). A final group of 15 female Lewis rats received no injections or treatment and were designated as the naïve group. Induction of uveitis was confirmed by clinical examination and identification of ocular inflammation on day 2 for PMU animals and day 14 for EAU animals. On day 2, postintravitreal injection animals were anesthetized and enucleated. Ten microliters of aqueous humor was aspirated and mixed with 1.1 lL 10X protease inhibitor. The vitreous was separated from the retina, homogenized with a tissue lyser in 150 lL PBS and 16 lL 10X protease inhibitor. All samples were stored at À808C.
Induction of EAU in Lewis rats was initiated with a subcutaneous injection of 30 lg synthetic bovine IRBP peptide (residue sequence ADGSSWEGVGVVPDV) in complete Freund's adjuvant (2.5 mg/mL mycobacterium) in the right hind flank. 16 The animal study protocol was approved by the Animal Care and Use Committee of the University of Washington (animal study protocol No. 4180-04). All experiments performed in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Sample Preparation for Protein Analysis
Aqueous and vitreous were collected and pooled from 15 eyes from each treatment group. Samples were collected from naïve animals on day 0, from PMU on day 2, and from EAU on day 14. These time points were chosen for the animals with uveitis, as these times correlated with maximal inflammation observed in each model (data submitted in accompanying manuscript). From individual eyes, aqueous was aspirated and protease inhibitor added. The vitreous was separated from the retina, diluted in 150 lL PBS and 1X protease inhibitor (SigmaAldrich Corp., St. Louis, MO, USA), and homogenized. The sample was spun down for 1 minute at 16,000g, and supernatant was collected. All samples were stored at À808C before testing. From half the pool, protein was precipitated by adding an equal volume of 20% trichloroacetic acid and incubating on ice for 30 minutes. The samples were centrifuged at 48C for 15 minutes at 16,000g, and the supernatant was discarded. The pellet was washed two times with acetone and then centrifuged at 48C for 5 minutes at 16,000g. Protein resolubilization was achieved with ReadyPrep Rehydration Sample Buffer (8 M urea, 2% CHAPS, 50 mM dithiothreitol, 0.2% Bio-Lyte 3/10 ampholytes, trace bromophenol blue) from Bio-Rad (Hercules, CA, USA) for traditional 2-D gel electrophoresis and in buffer containing 7 M urea, 2 M thiourea, 30 mM Tris, 4% CHAPS, pH 8.5, for differential gel electrophoresis (DIGE). Protein concentration was measured by Pierce 660 nm Protein Assay from Thermoscientific (Rockford, IL, USA).
Two-Dimensional Polyacrylamide Gel Electrophoresis and Mass Spectrometry
Thirty micrograms of the pooled and resolubilized protein was added to rehydration buffer and incubated overnight with an 11-cm immobilized pH gradient strip (3-10 pH IPG strip; BioRad) at room temperature. Isoelectric focusing was performed on a Bio-Rad IEF cell at 8000 V until 20,000 V-hours was reached. The second dimension was performed by using 10% to 20% Tris-HCl gels. Gels were stained with Bio-Safe Coomassie Stain (Bio-Rad). Spots of interest from 2-D gels of naïve and PMU samples were excised. Protein spots were double washed in a solution of 50% methanol, 5% acetic acid and then reduced in 10 mM dithiothreitol and alkylated in 100 mM iodoacetamide. Finally, the protein spots were digested in trypsin and submitted for analysis by liquid chromatographytandem mass spectrometry. 17 
Two-Dimensional DIGE
Fifty micrograms of protein for each sample was labeled with 400 pmol cyanine dye 2 (Cy2), Cy3, or Cy5. The manufacturer's suggestions were followed for CyDye labeling (GE Healthcare, Pittsburgh, PA, USA). Immobiline dry strips (18-cm IPG pH 3-10 nonlinear; GE Life Sciences, Pittsburgh, PA, USA) were rehydrated with rehydration buffer (7 M urea, 2 M thiourea, 2% CHAPS, 2% IPG buffer, 2.8% DTT, trace bromophenol blue) and the pooled dyed samples overnight. The isoelectric focusing step was run on a Bio-Rad IEF cell at 250 V for 15 minutes, 1000 V for 1 hour, 8000 V for 3 hours, 8000 V until 25 kV-hours was reached. The second dimension was run on precast 4% to 20% Tris-glycine gels in low fluorescence glass (Jule, Inc., Milford, CT, USA) at a constant current of 24 mA for 6.5 hours at 48C. Images were scanned on a Typhoon FLA 9000 scanner (GE Life Sciences).
Western Blot
Samples were loaded in equal volume of original pooled sample (0.7 lL aqueous per lane or 5 lL vitreous per lane) or in equal protein concentration (5 lg total protein per lane). All samples were loaded in a final volume of 40 lL in PBS. For Supplementary Figure S1 , the aqueous humor was centrifuged at 250g at room temperature for 7 minutes. The supernatant fraction was collected and an appropriate volume of 10X protease inhibitor was added for a final concentration of 1X (1-1.5 lL). The cell pellet was washed with 1X PBS three times and then resuspended in 15 lL 1X PBS containing 1X protease inhibitor. Samples were separated on 4% to 12% Bis-Tris Gels from Invitrogen (Grand Island, NY, USA) in NuPage MES SDS running buffer (50 mM MES, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.3) at 200 V for 40 minutes and then transferred to Pierce Nitrocellulose membrane (Thermoscientific) overnight at 14 V at 48C. Membranes were blocked with 5% milk 1% BSA in Trisbuffered saline, 0.05% Tween 20 for 1 hour at 48C. Blots were incubated overnight with primary antibodies at 48C with shaking. Primary antibodies included goat anti-S100A8/calgranulin A (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), goat anti-S100A9/calgranulin B (1:200; Santa Cruz Biotechnology), and rabbit anti-albumin (1:60,000; Abcam, Cambridge, MA, USA). Blots were then washed three times in 1X TBS with 0.05% Tween-20 at room temperature and then incubated at room temperature for 1 hour with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (1:10,000, goat anti-rabbit HRP conjugated; Sigma-Aldrich Corp.), donkey polyclonal anti-goat HRP conjugated (1:20,000 for anti-S100A8 and 1:40,000 for anti-S100A9; Abcam). Blots were then washed five times in 1X TBS with 0.05% Tween-20 and once in 1X TBS at room temperature and then secondary antibody was detected by using chemiluminescent substrate (Thermoscientific) for 5 minutes at room temperature.
RESULTS

Inflammation Increases Protein Concentration but Decreases Protein Complexity
After induction of uveitis, the protein concentration of the aqueous and vitreous were measured and compared to control eyes. The protein levels were the lowest in naïve eyes with total protein concentrations of 1.18 lg/lL in the aqueous (AqH) and 1.17 lg/lL in the vitreous (Table) . The EAU eyes had the highest protein concentration in the AqH (22.17 lg/lL) and vitreous (43.50 lg/lL). Protein concentration was also increased in PMU eyes, to 11.56 lg/lL in the AqH and 10.2 lg/ lL in the vitreous. Sham injection (3.41 lg/lL) increased the AqH protein nearly 3-fold when compared to naïve condition (1.18 lg/lL), but vitreous protein concentration was not affected (naïve, 1.70 lg/lL).
The protein constituents of the aqueous humor in naïve and inflamed (EAU and PMU) eyes were then compared by using DIGE (Fig. 1) . Proteins from naïve eyes were labeled with Cy2 (Fig. 1A, blue) , PMU with Cy5 (Fig. 1C, red) , and EAU with Cy3 (Fig. 1B, green) . Albumin was identified as a major component of the aqueous in all conditions (Fig. 1D, asterisk) . More individual spots were identified in the naïve aqueous than in either inflamed condition. For example, a large number of spots located in the 20-to 25-kDa range with an isoelectric focusing point of pH of 5 to 6.6 were detected in the naïve aqueous, but not in PMU or EAU aqueous (Fig. 1D, bracket) . This suggests there is a decreased protein complexity in the inflamed aqueous. Some of the proteins found in the naïve aqueous were still present in the inflamed conditions (Fig. 1D , white spots). However, differential concentrations are indicat- ed for many of these proteins by the relative fluorescent intensities on the merged image. Some proteins are specific for inflammation and were present in both PMU and EAU, but not in naïve samples (Fig.  1D, open arrow) . Rare proteins were specific to EAU (Fig. 1D , closed arrow) or PMU (Fig. 1D, closed arrowhead) , but many of the proteins that were expressed in inflammation were expressed in both models. The EAU spot intensity was often qualitatively increased compared to PMU spot intensity, leading to green spots on the merged image (Fig. 1D, open  arrowheads) .
Identification of Differentially-Expressed Aqueous Proteins During Inflammation
To further identify the differentially-expressed proteins, twodimensional gel electrophoresis was performed on PMU and naïve aqueous, and spots of interest were excised and identified by mass spectrometry (Fig. 2) . By comparing the two gels, three categories of proteins could be identified: proteins that were present in PMU and not naïve aqueous (group 1), proteins present in naïve aqueous and not PMU (group 2), and proteins present in both (group 3). Seventeen spots that demonstrated differential expression between PMU and naïve eyes were identified by mass spectrometry and grouped by expression pattern (table in Fig. 2 ). Group 1 (spots 1-4), consists of three proteins: S100A9 (14 kDa), protein S100A8 (10.8 kDa), and apolipoprotein E (ApoE; 36 kDa). S100A9 was identified twice at the same molecular weight, but at two different isoelectric focusing points. Group 2 proteins include lacrimal gland protein (9.8 kDa), a2l-globulin 
Upregulation of Protein S100A8 and Protein S100A9
Western blot analysis was used to confirm the differential expression of proteins identified by mass spectrometry. Naïve, sham injection, PMU, and EAU aqueous and vitreous were tested to determine dependency of protein changes on experimental condition. Samples were tested in parallel by loading equal volume or equal protein concentration per well. Equal volume samples reflect the concentration of the protein found inside the eye, while equal protein samples reflect the relative abundance of the protein in relation to all other proteins in the sample. Serum albumin was used as loading control for these experiments. In the equal volume experiments, serum albumin was markedly increased in the inflamed conditions (PMU and EAU) compared to naïve and sham injection.
Both S100A8 and S100A9 were identified by 2-D gel electrophoresis and mass spectrometry (spots 1-3) as present in PMU and not naïve aqueous. These results were confirmed by Western blot analysis in the aqueous humor (Figs. 3A, 3C ) and vitreous (Figs. 3B, 3D ) humor in both EAU and PMU (Fig.  3) . Qualitatively, both S100A8 and S100A9 are more abundant in the aqueous than the vitreous. The different information provided by the equal volume and equal protein is most striking in the vitreous experiment (Fig. 3B) . Although the S100 proteins were present in the EAU vitreous at equal volume, when an equal protein concentration was compared, the amount of the S100 proteins was nearly undetectable in EAU while still present in PMU. Table of proteins identified specifically in PMU or naïve aqueous and proteins found in both. Two-dimensional gels from naïve aqueous (blue) and PMU aqueous (red). The gels are overlayed in the bottom panel with a slight offset for comparison. Protein spots of interest (indicated by arrows) were excised and identified by mass spectrometry. Spots 1 to 4 were excised from the PMU gel and spots 5 to 18 were excised from the naïve gel.
To determine if S100A9 in the PMU aqueous is present primarily in an extracellular secreted form, or within the cells of the inflammatory infiltrate, we separated the cellular and supernatant fractions of the aqueous humor by centrifugation and tested each fraction for the presence of S100A9 protein ( Supplementary Fig. S1 ). S100A9 protein was only detected in the cellular fraction.
A second protein from group 1 (present in PMU not naïve aqueous) is ApoE. In the aqueous, low levels of ApoE were found in naïve eyes in the equal protein condition, but it was undetectable in the equal volume condition. Apolipoprotein E was present in the aqueous of both PMU and EAU, but had higher protein levels in EAU than in PMU. Vitreous levels of ApoE were much lower than aqueous levels in all conditions. Beta-B2-crystallin was identified among the group 3 proteins (present in naïve and PMU). Beta-B2-crystallin was notably decreased in the EAU aqueous when compared to PMU, sham, and naïve. In the vitreous, b-B2-crystallin was present in all conditions by equal volume, but the equal protein comparison identified a similar marked decrease in EAU when compared with the other conditions.
DISCUSSION
Uveitis encompasses a heterogenous group of diseases. Mechanisms driving the underlying ocular inflammation are likely shared in most diseases, but as evidenced by variable responses to therapy there must also be disease-specific mediators. In this study, we explored the proteome of two models of uveitis to identify proteins that may be common to most forms of inflammation, and those that show model or mechanism specificity.
In uveitis, the immunologic and physical barriers breakdown between the eye and the blood, leading to an increase in protein content of intraocular fluids. In humans this process is recognized clinically as flare. 18 Previous studies in the rat EIU and EAU models, as well as in ERU, have looked for proteome changes in the vitreous during inflammation. 13, 14, 19 For this study, we decided to look at protein changes in the aqueous of two rat models of uveitis by using DIGE and matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF). We found that the aqueous protein composition during inflammation is distinct from the naïve composition and that select proteins appear to be differentially upregulated in each uveitis model. These data support the previous studies identifying a different aqueous proteome in an inflamed eye when compared to the naïve proteome, and they support the hypothesis that different forms of inflammation (PMU versus EAU) can have unique protein components as part of their mechanism of disease. Differential gel electrophoresis also identified an overall decrease in the complexity of the protein constituents in the aqueous of inflamed eyes when compared to naïve aqueous. In the inflamed eye, the blood-retinal barrier is disrupted and major serum proteins such as albumin and IgG are known to increase in the vitreous. 20, 21 This can make detection of less prevalent proteins difficult. However, in our case we found that the proteins S100A8, S100A9, and ApoE were still detectably increased in the inflamed condition, suggesting a significant increase in the levels of these proteins.
In both the PMU and EAU models of uveitis, S100A8 and S100A9 were found in high levels in both the aqueous and . Western blot analysis of aqueous proteins. Aqueous humor and vitreous samples from naïve, sham intravitreal injection, PMU, and EAU animals were tested for the presence of individual proteins. Samples were tested both when an equal volume of sample (equal volume) and an equal concentration of total protein (equal protein) were loaded. Serum albumin was used as a loading control for each gel (top). (A) S100A9 and S100A8 are present in inflamed aqueous only. (B) S100A9 and S100A8 are present in inflamed vitreous only and are a more significant component of total vitreous protein in PMU than in EAU. (C) Apolipoprotein E is present at low levels in naïve and sham aqueous, but is significantly increased in the aqueous of PMU and EAU. Beta-B2-crystallin was present in the aqueous of naïve and sham, but was increased in PMU. In EAU, b-B2-crystallin was decreased in comparison with naïve and sham. (D) In the vitreous, ApoE was present in EAU, but did not show a significant elevation in overall concentration. In the vitreous, b-B2-crystallin was present in all conditions, but relative concentration decreased in EAU more than PMU when compared to naïve.
vitreous by Western blot. However, in the equal protein comparison in the vitreous, S100A8 and S100A9 were markedly more increased in PMU than in EAU. S100A8 and S100A9 form a complex called calprotectin, which is secreted by phagocytes during the host response to infection, inflammation, and during metastatic cancer spread. 22 Calprotectin has been associated with a wide variety of human diseases including rheumatoid arthritis, juvenile idiopathic arthritis, sepsis, inflammatory bowel disease, vasculitis, and prostate cancer. [22] [23] [24] [25] Intracellularly, S100A8/S100A9 tetramers interact with cytoskeleton components in a calciumdependent manner to promote stabilization of tubulin filaments during phagocyte transendothelial migration. 26 Extracellularly, the heterodimers can also function as danger-associated molecular pattern (DAMP) by signaling through the TLR4 receptor. 27 S100A8/S100A9 is normally found within phagocytes, during an inflammatory response. Histologic analysis of the PMU model has demonstrated neutrophils and macrophages infiltrating the eye on day 2 (accompanying manuscript), and our data would suggest that most of this heterodimer remains in the intracellular compartment during ocular inflammation. However, there is evidence that even low levels of extracellular S100A8/S100A9 can induce a proinflammatory state in endothelial cells that includes increased vascular permeability, upregulation of leukocyte adhesion molecules, increased proinflammatory cytokine expression, and neutrophil chemotaxis. [28] [29] [30] [31] Phagocytes are not the only source of S100A8/S100A9, as epidermal cells from patients with systemic lupus erythematosus and psoriasis also release these proteins, and may be the source of increased serum levels in these patients. 32, 33 Future experiments will be directed at determining the sources of S100A8/S100A9 in the anterior chamber.
In addition to human studies, in the mouse model experimental antigen-induced arthritis, S100A9/S100A8 is highly induced and is expressed by chondrocytes. 34, 35 Mice mutant for S100A9 (which also leads to a functional loss of S100A8) have markedly decreased disease severity and neutrophil infiltrate into the joint during arthritis induction. In the EIU model in rats, administration of anti-S100A9/ S100A8 antibody significantly decreases disease severity and inflammatory cell infiltration into the eye, supporting a role for extracellular S100A8/S1000A9 in this form of ocular inflammation. 36 In conjunction with the data we present on the presence of S100A8/S100A9 in both PMU and EAU, it is likely that this complex is an important mediator of ocular inflammation for many forms of uveitis, and therefore may be a good target for immunomodulatory therapy. Tasquinimod is a second-generation quinolone-3-carboxamide with a high affinity for binding and sequestering S100A9 that is currently in clinical trials in patients with castration-resistant (advanced) prostate cancer. 23 One therapeutic mechanism of action of tasquinimod is to block TLR4 binding and activation by S100A9, which stimulates tumor invasion by proangiogenic myeloid-derived suppressor cells. 23, 37 It remains to be tested if tasquinimod could have similar effects on blocking tissue entry by other types of inflammatory cells in autoimmune processes.
We identified increased protein levels of ApoE in the aqueous in both models of uveitis. Apolipoprotein E is a 34-kDa glycoprotein that plays a central role in lipid metabolism by functioning as a ligand for low-density-lipoprotein receptors and participating in extracellular cholesterol and triglyceride transport. 38 Subsequently, additional roles for ApoE have been identified in neurodegeneration and inflammation in Alzheimer's disease and multiple sclerosis. 39, 40 In the eye, ApoE and its isoforms have also been linked to age-related eye diseases that are believed to have an immune component, such as macular degeneration 41, 42 and primary open angle glaucoma, 43, 44 but no role in uveitis has been identified previously. At this time, it is unclear if the ApoE in the eye is a product of increased local production by astrocytes, microglia, and macrohphages, 45, 46 or a result of an influx of systemic ApoE that follows owing to the bloodretinal barrier's breakdown associated with ocular inflammation. 47, 48 Optic nerve crush injuries produce increased levels of ApoE, so it is also possible that the increased ApoE levels may be a surrogate of intraocular neuronal injury, rather than part of a neuroinflammatory mechanism. However, owing to the more significant destruction of the neural retina in EAU, we would have expected that the differences in ApoE levels would be greater if they were only a surrogate of neuronal injury. Further studies will need to be performed to determine which of these mechanisms leads to the increased intraocular ApoE levels seen in both PMU and EAU.
We identified differential expression of many crystallin proteins between the inflamed and naïve conditions. Many of the crystallins were not detectable in the inflamed aqueous when compared with the naïve condition. These findings are consistent with previous reports of changes in crystallin expression detected in models of ocular inflammation. 13, 14, [49] [50] [51] [52] Crystallins are the major structural proteins of the lens and are grouped into three families: the a-, b-, and c-crystallins. 53 However, crystallins are not lensexclusive proteins and are also expressed in the neural retina 54, 55 and in select extraocular tissues. [56] [57] [58] The aA-and aB-crystallins are members of the small heat shock family of proteins and have been shown to play a role in preventing neuronal apoptosis in response to multiple forms of cell stress. 59 The b-crystallins are Greek key motif-containing proteins. This motif is composed of antiparallel b pleated sheets that allows for optically transparent protein packing in the lens 60 and Caþ binding. 61 Like a-crystallins, members of the b-crystallin family are also upregulated in response to cellular stresses, but rather than performing an antiapoptotic role, they seem to be important in neural regeneration. 62 In this study, we found that b-B2-crystallin levels decreased in the AqH and vitreous in the EAU uveitis model at the time of peak inflammation (day 14). This is in contrast to previous work that has reported the upregulation of aA-and b-B2-crystallin in mitochondria during the early stages of EAU. 49 However, these results could be reconciled by considering that EAU is an overwhelming panuveitis that leads to significant retinal necrosis, such that by the time of peak inflammation, any increased expression of b-B2-crystallin may not be detectable above the background loss of the protein as retinal cells are destroyed. This temporal association of changes in b-B2-crystalline, together with the data identifying a neuroprotective and antiapoptotic role for crystallins in the eye, suggests that supplementing crystallin function during active inflammation could be an adjunctive therapy for patients with uveitis.
Both models tested in this study were relatively acute (2 days for PMU and 2 weeks for EAU) and are self-limited. We chose to study the rat because of the relatively larger amounts of ocular fluid available than with mouse. At present, there are no validated chronic uveitis models or spontaneous uveitis models in the rat. It is possible the proteome of chronic inflammation differs substantially from that seen in the acute condition and may suggest a different set of molecular targets for therapy. Further work on development of tractable animal models of uveitis is needed to address this and other important questions.
